Market revenue in 2023 | USD 2,503.8 million |
Market revenue in 2030 | USD 4,943.4 million |
Growth rate | 10.2% (CAGR from 2023 to 2030) |
Largest segment | Consumables |
Fastest growing segment | Consumables |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Services, Instruments, Consumables |
Key market players worldwide | Abbott Laboratories, Roche Holding AG, GE HealthCare Technologies Inc Common Stock, Qiagen NV, Becton Dickinson & Co, Koninklijke Philips NV, Siemens Healthineers AG ADR, Hologic Inc, Thermo Fisher Scientific Inc, Illumina Inc |
Consumables was the largest segment with a revenue share of 59.95% in 2023. Horizon Databook has segmented the India cancer diagnostics market based on services, instruments, consumables covering the revenue growth of each sub-segment from 2018 to 2030.
Several key players are focusing on developments to provide diagnostic tests in India. For instance, in March 2023, Roche Diagnostics India entered into an agreement with the Cancer Awareness Prevention and Early Detection Trust (CAPED) to promote cancer prevention, awareness, and early detection.
Similarly, in September 2022, AstraZeneca India and the CAPED Trust launched the Ganga Godavari Cancer Screening Program to reduce India’s cancer burden. This would further create major opportunities in the local cancer diagnostics market.
On the other hand, increasing support from government funding agencies is expected to propel market growth. The Department of Biotechnology (DBT) plays an important role in managing and controlling cancer in India.
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account